Thymosin alpha 1 is a small protein made up of 28 amino acids, naturally produced by the thymus gland, that plays a central role in regulating the immune system. It works primarily by helping immune cells mature and become more active, which is why synthetic versions have been studied and used clinically for conditions ranging from chronic hepatitis to cancer. While it’s approved in over 30 countries for various immune-related conditions, it has not been approved by the U.S. Food and Drug Administration.
Where It Comes From
The thymus is a small organ behind your breastbone that is most active during childhood and gradually shrinks with age. It serves as a kind of training ground for T-cells, the white blood cells responsible for identifying and attacking infections and abnormal cells. Thymosin alpha 1 was first isolated from thymus tissue in the 1970s as part of a mixture called “thymosin fraction 5.” Researchers eventually identified it as one of the key active components, a 28-amino-acid chain with a chemically modified starting point (an acetylated serine residue, for the biochemistry-minded).
As the thymus shrinks with age, natural production of thymosin alpha 1 declines. This decline tracks with the broader weakening of immune function in older adults. The synthetic version, sometimes marketed under the brand name Zadaxin (generic name: thymalfasin), is designed to replicate what the body produces less of over time.
How It Works in the Immune System
Thymosin alpha 1 doesn’t attack pathogens directly. Instead, it acts as an immune modulator, fine-tuning the activity of several types of immune cells so they respond more effectively.
Its most well-studied effect is on T-cells. It promotes the maturation of immature T-cells and increases activation of both CD4+ (helper) and CD8+ (killer) T-cells. In practical terms, this means the body gets better at recognizing threats and mounting a targeted response. It also boosts production of key signaling molecules, particularly interleukin-2 and interferon-gamma, which coordinate the broader immune response.
Beyond T-cells, thymosin alpha 1 restores the activity of natural killer (NK) cells, another frontline defense. In animal cancer models, researchers found that when NK cells were depleted, the benefits of thymosin alpha 1 disappeared entirely, confirming that much of its effect works through these cells. It also influences dendritic cells, which act as messengers that present threats to the rest of the immune system, helping them mature and function more efficiently.
Chronic Hepatitis B and C
The most established clinical use for thymosin alpha 1 is in treating chronic viral hepatitis, particularly hepatitis B. A meta-analysis of randomized controlled trials comparing it to interferon-alpha (a standard treatment) found an interesting pattern: during the six months of active treatment, interferon appeared to work slightly better. But six months after treatment ended, patients who had received thymosin alpha 1 were roughly 3.7 times more likely to show a sustained viral response and about 2.7 times more likely to achieve a complete response, meaning both viral clearance and normalization of liver enzymes.
This delayed but durable response is a signature feature of thymosin alpha 1. Rather than suppressing the virus directly, it trains the immune system to control it on its own, which is why the benefits tend to emerge and persist after the treatment course ends. Interferon-alpha, by comparison, produces initial response rates of 30 to 40%, but those gains don’t always hold.
Cancer Treatment Support
Thymosin alpha 1 is not a standalone cancer treatment. Its role in oncology is as an adjuvant, something given alongside other therapies to improve outcomes. The rationale is straightforward: chemotherapy and radiation suppress the immune system, and thymosin alpha 1 can help restore it.
A study in patients with liver cancer (hepatocellular carcinoma) who had undergone surgical removal of their tumors compared three groups: those receiving immunotherapy plus thymosin alpha 1, immunotherapy alone, and no adjuvant treatment. The combination group had dramatically better outcomes. Their one-year recurrence-free survival rate was 98.4%, compared to 86.2% for immunotherapy alone and 49.2% for the control group. At two years, the gap widened further: 80.2% versus 65.8% versus 24.6%. Overall survival followed a similar pattern, with the combination group showing 100% survival at both one and two years.
Side effects in that study were mild. The most common were skin reactions like rash or itching (21.5%) and diarrhea (18.5%). Serious (grade 3) side effects were rare, each occurring in less than 2% of patients, and no severe or life-threatening adverse events were recorded.
The COVID-19 Experience
During the pandemic, thymosin alpha 1 was tested in hospitalized COVID-19 patients based on its known ability to restore T-cell function. Early small studies were encouraging, with one retrospective study of 76 severe cases finding that it increased T-cell counts and was associated with reduced mortality. However, larger and more rigorous studies told a different story.
A multicenter cohort study found that after adjusting for confounding factors, thymosin alpha 1 use was actually associated with a 50% higher rate of non-recovery. This risk was even more pronounced in the sickest patients: those admitted to ICUs showed a fivefold increase in non-recovery risk. The likely explanation is not that thymosin alpha 1 caused harm directly, but that boosting immune activation in patients already experiencing severe inflammatory responses may have worsened the problem. COVID-19’s most dangerous phase involves the immune system overreacting, not underperforming, making an immune booster potentially counterproductive in that specific context.
How It’s Given
Thymosin alpha 1 is administered as a subcutaneous injection, typically in the upper arm, thigh, or abdomen. The standard dose is 1.6 mg injected twice weekly, a regimen usually maintained for 6 to 12 months depending on the condition being treated. For patients weighing under 40 kilograms (about 88 pounds), the dose is adjusted to 40 micrograms per kilogram of body weight. Some compounding protocols use a slightly different schedule of 1.5 mg every third day.
Regulatory Status
Thymosin alpha 1 occupies an unusual regulatory space. It’s approved in dozens of countries across Asia, South America, and parts of Europe for hepatitis, cancer support, and immune deficiency. In the United States, the FDA granted it orphan drug designation in 2000 for the treatment of hepatocellular carcinoma, but it has never received full FDA approval for any indication. This means it’s not commercially available as an FDA-approved medication in the U.S., though it has been accessible through compounding pharmacies.
The distinction matters because compounded versions are not subject to the same manufacturing and quality controls as FDA-approved drugs. In 2024, the FDA began scrutinizing bulk compounding of thymosin alpha 1 more closely, raising questions about its continued availability through that channel. For people outside the U.S., access depends on the regulatory framework in their country, where it may be a standard prescription medication.
Who It May Help and Who Should Be Cautious
The strongest evidence supports thymosin alpha 1 for people with chronic hepatitis B, particularly those who haven’t responded well to other treatments, and as immune support alongside cancer therapies in settings where the immune system needs rebuilding. It’s also been studied in older adults and immunocompromised patients as a way to improve vaccine responses.
People with autoimmune conditions or those taking immunosuppressive medications after organ transplants should be cautious, since boosting immune activity could worsen autoimmune flares or trigger rejection of a transplanted organ. The COVID-19 data also serves as a reminder that immune stimulation is not always beneficial: in conditions driven by excessive inflammation, amplifying the immune response can do more harm than good.